Author’s response to reviews

Title: Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy

Authors:

Tatsuzo Mizukami (mizukami4977@yahoo.co.jp)
Hirofumi Kamachi (hkamachi@db3.so-net.ne.jp)
Tomoko Mitsuhashi (mitsut74@huhp.hokudai.ac.jp)
Yosuke Tsuruga (ytsuruga@d2.dion.ne.jp)
Yutaka Hatanaka (yhatanaka@huhp.hokudai.ac.jp)
Toshiya Kamiyama (t-kamiya@med.hokudai.ac.jp)
Yoshihiro Matsuno (ymatsuno@med.hokudai.ac.jp)
Akinobu Taketomi (taketomi@med.hokudai.ac.jp)

Version: 7 Date: 9 September 2014

Author’s response to reviews: see over
September 9, 2014

Dear Editor *BMC Cancer*

We are pleased to submit the revised version of our manuscript:
“Immunohistochemical analysis of cancer stem cells in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy”

We are very grateful to you that I had a peer review of this manuscript.

We have revised the manuscript according to the comments from editors.

We now hope that our paper will be suitable for publication in *BMC Cancer* and look forward to hearing from you concerning your editorial decision.

Sincerely yours,

Tatsuzo Mizukami

Department of Gastroenterology Surgery I, Graduate School of Medicine, Hokkaido University.

e-mail: mizukami4977@yahoo.co.jp
Response to the Editorial Comments

1. …, however in the current version of your manuscript, you have removed your additional files, please include these in your manuscript. In addition we ask you to format your figure legends, so that they go straight after you references rather than within the manuscript text. We also ask you to provide legends for your additional files after your references. …

Reply 1: We are very sorry for not following your advice and guidelines. According to your suggestion, we added figures and figure legends to our manuscript and have changed the text as follows “Regarding the prognosis in the NACRT group, there are no significant differences in DFS (Figure S1) and OS (Figure S2) in almost all CSCs marker expect CD133.” (P14 lines 20-22).